Patients with non-small cell lung cancer(NSCLC)harboring epidermal growth factor receptor(EGFR)mutations show a notable response to tyrosine kinase inhibitor(TKI)treatment.However,almost all patients eventually develo...Patients with non-small cell lung cancer(NSCLC)harboring epidermal growth factor receptor(EGFR)mutations show a notable response to tyrosine kinase inhibitor(TKI)treatment.However,almost all patients eventually develop resistance[1].Given the limited post-resistance treatment options,identifying effective solutions for this sizable group has become a pressing clinical concern.The emergence of immunotherapy has marked a significant breakthrough for patients with NSCLC without driver gene mutations.However,its efficacy remains a subject of debate on the carriers of EGFR mutation.While preclinical studies have hinted at the potential benefits of immunotherapy for patients with EGFR mutations,early clinical investigations have painted a less optimistic picture[2,3].展开更多
基金supported by the China Postdoctoral Science Foundation(2023M742119)the National Natural Science Foundation of China(82403395,82373319,and 82102766)+2 种基金the Natural Science Foundation of Shandong Province(ZR2024QH219)the National Key Clinical Program on Oncologythe Shanghai Science and Technology Innovation Action Plan Medical Innovation Research Special Project(23Y11908600)。
文摘Patients with non-small cell lung cancer(NSCLC)harboring epidermal growth factor receptor(EGFR)mutations show a notable response to tyrosine kinase inhibitor(TKI)treatment.However,almost all patients eventually develop resistance[1].Given the limited post-resistance treatment options,identifying effective solutions for this sizable group has become a pressing clinical concern.The emergence of immunotherapy has marked a significant breakthrough for patients with NSCLC without driver gene mutations.However,its efficacy remains a subject of debate on the carriers of EGFR mutation.While preclinical studies have hinted at the potential benefits of immunotherapy for patients with EGFR mutations,early clinical investigations have painted a less optimistic picture[2,3].
